[1] EKSTEDT M, HAGSTRÖM H, NASR P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology, 2015, 61(5):1547-1554.
[2] DOWMAN J K, TOMLINSON J W, NEWSOME P N.Pathogenesis of non-alcoholic fatty liver disease[J]. QJM, 2010, 103(2):71-83.
[3] BUZZETTI E, PINZANI M, TSOCHATZIS E A.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048.
[4] DASARATHY S, DASARATHY J, KHIYAMI A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis:a prospective study[J]. J Hepatol, 2009, 51(6):1061-1067.
[5] van WERVEN J R, MARSMAN H A, NEDERVEEN A J, et al. Assessment of hepatic steatosis in patients undergoing liver resection:comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved1H MR spectroscopy[J]. Radiology, 2010, 256(1):159-168.
[6] LOOMBA R.Role of imaging-based biomarkers in NAFLD:recent advances in clinical application and future research directions[J]. J Hepatol, 2018, 68(2):296-304.
[7] KIM M, KANG B K, JUN D W.Comparison of conventional sonographic signs and magnetic resonance imaging proton density fat fraction for assessment of hepatic steatosis[J]. Sci Rep, 2018, 8(1):7759.
[8] HERNAEZ R, LAZO M, BONEKAMP S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver:a meta-analysis[J]. Hepatology, 2011, 54(3):1082-1090.
[9] COCCIOLILLO S, PARRUTI G, MARZIO L.CEUS and fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. World J Hepatol, 2014, 6(7):496-503.
[10] SERRA-BURRIEL M, GRAUPERA I, TORAN P, et al. Transient elastography for screening of liver fibrosis:cost-effectiveness analysis from six prospective cohorts in Europe and Asia[J]. J Hepatol, 2019, 71(6):1141-1151.
[11] CHUAH K H, LAI L L, VETHAKKAN S R, et al. Liver stiffness measurement in non-alcoholic fatty liver disease:two is better than one[J]. J Gastroenterol Hepatol, 2020, Aug;35(8):1404-1411.
[12] BATTAGLIA V, CERVELLI R.Liver investigations:updating on US technique and contrast-enhanced ultrasound(CEUS)[J]. Eur J Radiol, 2017, 96:65-73.
[13] JUN B G, PARK W Y, PARK E J, et al. A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis[J]. PLoS One, 2017, 12(8):e0182784.
[14] KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66:1022-1030.
[15] JUNG K S, KIM B K, KIM S U, et al. Factors affecting the accuracy of controlled attenuation parameter(CAP) in assessing hepatic steatosis in patients with chronic liver disease[published correction appears in PLoS One, 2014, 9(8):e107331].Cheon, Kyung Hyun[corrected to Chun, Kyeong Hyeon] [J]. PLoS One, 2014, 9(6):e98689.
[16] CAUSSY C, BRISSOT J, SINGH S, et al. Prospective, same-day, direct comparison of CAP with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging proton density fat fraction as the standard[J]. Clin Gastroenterol Hepatol, 2019, S1542-3565(19):31434-X.
[17] WONG V W, IRLES M, WONG G L, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease[J]. Gut, 2019, 68(11):2057-2064.
[18] NOGAMI A, YONEDA M, KOBAYASHI T, et al. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease[J]. Hepatol Res, 2019, 49(8):872-880.
[19] DARWEESH S K, OMAR H, MEDHAT E, et al. The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients:a biopsy-controlled study[J]. Eur J Gastroenterol Hepatol, 2019, 31(8):1010-1016.
[20] JIANG W, HUANG S, TENG H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease:a meta-analysis[J]. BMJ Open, 2018, 8(8):e021787.
[21] KRAMER H, PICKHARDT P J, KLIEWER M A, et al. Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques:prospective comparison with MR spectroscopy[J]. AJR Am J Roentgenol, 2017, 208(1):92-100.
[22] PAIGE J S, BERNSTEIN G S, HEBA E, et al. A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease[J]. AJR Am J Roentgenol, 2017, 208:W168-W177.
[23] TADA T, IIJIMA H, KOBAYASHI N, et al. Usefulness of attenuation imaging with an ultrasound scanner for the evaluation of hepatic steatosis[J]. Ultrasound Med Biol, 2019, 45(10):2679-2687.
[24] SHEN Y Y, XING Y C, LIN H M, et al. Quantitative analysis of non-alcoholic fatty liver in rats via combining multiple ultrasound parameters[J]. Math Biosci Eng, 2019, 16(5):4546-4558.
[25] PARK Y S, PARK S H, LEE S S, et al. Biopsy-proven nonsteatotic liver in adults:estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT[J]. Radiology, 2011, 258(3):760-766.
[26] ARTZ N S, HINES C D, BRUNNER S T, et al. Quantification of hepatic steatosis with dual-energy computed tomography:comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse[J]. Invest Radiol, 2012, 47(10):603-610.
[27] LEI P, JIAO J, LI H, et al. NAFLD evaluation:which is more appropriate, multislice computed tomography or ultrasound real-time shear wave elastography?[J]. J Xray Sci Technol, 2019, 27(5):871-883.
[28] COTLER S J, GUZMAN G, LAYDEN-ALMER J, et al. Measurement of liver fat content using selective saturation at 3.0 T[J]. J Magn Reson Imaging, 2007, 25(4):743-748.
[29] MOTOSUGI U, HERNANDO D, BANNAS P, et al. Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI[J]. J Magn Reson Imaging, 2015, 42(5):1241-1248.
[30] HERRERA R, PEÑALOZA F, ARRIETA C, et al. Cuantificación de esteatosis hepática no alcohólica por resonancia magnética[Quantification of liver fat infiltration by magnetic resonance] [J]. Rev Med Chil, 2019, 147(7):821-827.
[31] GU J, LIU S, DU S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:a meta-analysis[J]. Eur Radiol, 2019, 29(7):3564-3573.
[32] RUNGE J H, SMITS L P, VERHEI J J, et al. MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis[J]. Radiology, 2018, 286(2):547-556.
[33] SUN T, LIN X, CHEN K.Evaluation of hepatic steatosis using dual-energy CT with MR comparison[J]. Front Biosci(Landmark Ed), 2014, 19:1377-1385.
[34] COSTA-SILVA L, FEROLLA S M, LIMA A S, et al. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease[J]. Eur J Radiol, 2018, 98:82-89.
[35] LOOMBA R, CUI J, WOLFSON T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD:a prospective study[J]. Am J Gastroenterol, 2016, 111(7):986-994.
[36] LEFEBVRE T, WARTELLE-BLADOU C, WONG P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis[J]. Eur Radiol, 2019, 29(12):6477-6488.
[37] PAVLIDES M, BANERJEE R, TUNNICLIFFE E M, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity[J]. Liver Int, 2017, 37(7):1065-1073.
[38] EDDOWES P J, McDONALD N, DAVIES N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2018, 47(5):631-644. |
